Ralph Henry

Ralph Henry has a diverse and extensive work experience in the field of biopharmaceutics and corporate development. Starting in 1996, they worked as a Distinguished Professor in Biological Sciences at the University of Arkansas, where they led a cell and molecular biology laboratory and conducted research on protein routing and production technologies. During their time at the university, they co-founded InterveXion Therapeutics, an R&D company focused on developing antibody-based medicines for treating methamphetamine use disorder. In 2004, Ralph joined INTERVEXION THERAPEUTICS, LLC as an EVP of Biopharmaceutics and Corporate Development. In 2017, they moved on to VIC Technology Venture Development, where they held the position of VP Life Science and Medical Technology. Most recently, Ralph became the Chief Technology Officer at Kuria Therapeutics in 2022.

Ralph Henry obtained a Ph.D. in Membrane Protein Assembly from Kansas State University, where they studied from 1985 to 1991. Following this, they pursued a Postdoctoral degree in Protein targeting and transport at the University of Florida from 1992 to 1996. Prior to their Ph.D., Ralph completed their undergraduate studies at The University of Kansas, earning a BSE degree between 1979 and 1984. The field of study for their Bachelor's degree is not specified.